Daniel Dorgan

760 total citations · 1 hit paper
21 papers, 438 citations indexed

About

Daniel Dorgan is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Daniel Dorgan has authored 21 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 8 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in Daniel Dorgan's work include Cystic Fibrosis Research Advances (10 papers), Neonatal Respiratory Health Research (5 papers) and Tuberculosis Research and Epidemiology (4 papers). Daniel Dorgan is often cited by papers focused on Cystic Fibrosis Research Advances (10 papers), Neonatal Respiratory Health Research (5 papers) and Tuberculosis Research and Epidemiology (4 papers). Daniel Dorgan collaborates with scholars based in United States, Netherlands and France. Daniel Dorgan's co-authors include Denis Hadjiliadis, Patrick A. Flume, David E. Griffith, Doreen Addrizzo‐Harris, Renu Gupta, Gina Eagle, Richard J. Wallace, Kenneth N. Olivier, Charles L. Daley and Matthias Salathé and has published in prestigious journals such as Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine and Respiratory Medicine.

In The Last Decade

Daniel Dorgan

19 papers receiving 426 citations

Hit Papers

Inhaled mRNA therapy for treatment of cystic fibrosis: In... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study
    2023 82 citations Steven M. Rowe, Jonathan B. Zuckerman et al. Journal of Cystic Fibrosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Dorgan United States 9 172 163 162 89 75 21 438
Matthew M. Hewitt United States 7 180 1.0× 115 0.7× 225 1.4× 91 1.0× 40 0.5× 8 507
H. Blau Israel 10 231 1.3× 306 1.9× 140 0.9× 96 1.1× 117 1.6× 19 591
Deepti Singhal Australia 13 68 0.4× 79 0.5× 64 0.4× 117 1.3× 42 0.6× 17 607
Shahida Shahana Sweden 9 108 0.6× 66 0.4× 147 0.9× 133 1.5× 6 0.1× 13 409
Hung-An Ting United States 7 71 0.4× 50 0.3× 45 0.3× 126 1.4× 12 0.2× 8 433
M. Kousha United States 2 276 1.6× 149 0.9× 377 2.3× 47 0.5× 77 1.0× 6 500
Katleen Martens Belgium 11 52 0.3× 87 0.5× 105 0.6× 116 1.3× 6 0.1× 16 471
Ritu Nagpal India 16 121 0.7× 32 0.2× 79 0.5× 45 0.5× 90 1.2× 42 744
Brendan Dolan Sweden 12 25 0.1× 61 0.4× 45 0.3× 156 1.8× 27 0.4× 16 377
Manon Ruffin France 17 57 0.3× 420 2.6× 39 0.2× 200 2.2× 5 0.1× 30 679

Countries citing papers authored by Daniel Dorgan

Since Specialization
Citations

This map shows the geographic impact of Daniel Dorgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Dorgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Dorgan more than expected).

Fields of papers citing papers by Daniel Dorgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Dorgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Dorgan. The network helps show where Daniel Dorgan may publish in the future.

Co-authorship network of co-authors of Daniel Dorgan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Dorgan. A scholar is included among the top collaborators of Daniel Dorgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Dorgan. Daniel Dorgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hong, Gina, Scott G. Daniel, Jung‐Jin Lee, et al.. (2023). Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. Journal of Cystic Fibrosis. 22(4). 636–643. 8 indexed citations
3.
Rowe, Steven M., Jonathan B. Zuckerman, Daniel Dorgan, et al.. (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study. Journal of Cystic Fibrosis. 22(4). 656–664. 82 indexed citations breakdown →
4.
Taylor‐Cousar, Jennifer L., Raksha Jain, Terrence Sullivan, et al.. (2023). WS05.01 AAV mediated gene therapy for cystic fibrosis: interim results from a phase 1/2 clinical trial. Journal of Cystic Fibrosis. 22. S9–S9. 2 indexed citations
5.
Feng, Rui, Laurel Glaser, Ronald C. Rubenstein, et al.. (2023). The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis. Annals of the American Thoracic Society. 20(7). 984–992. 6 indexed citations
6.
7.
Tu, Vincent, Hsiaoju Lee, Kyle Bittinger, et al.. (2022). Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. Journal of Clinical Investigation. 132(18). 22 indexed citations
8.
Rowe, Steven M., Daniel Dorgan, Jorge Lascano, et al.. (2021). 544: Safety and tolerability of single and repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients. Journal of Cystic Fibrosis. 20. S257–S257. 2 indexed citations
9.
Douglas, Jennifer E., Alyssa M. Civantos, Denis Hadjiliadis, et al.. (2020). Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. International Forum of Allergy & Rhinology. 11(2). 201–203. 19 indexed citations
10.
Kil, Jonathan, Maria Gabriela Tupayachi Ortiz, Daniel Dorgan, et al.. (2020). Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation. Journal of Cystic Fibrosis. 20(2). 288–294. 14 indexed citations
11.
Krymskaya, Vera P., Andrew Courtwright, Daniel Dorgan, et al.. (2020). A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. Respiratory Medicine. 163. 105898–105898. 7 indexed citations
12.
Hong, Gina, Kevin Alby, Ronald C. Rubenstein, et al.. (2019). The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis. Journal of Cystic Fibrosis. 19(1). 125–130. 27 indexed citations
13.
Tebas, Pablo, Christopher Vinnard, Deborah Kim, et al.. (2019). Clinical Outcomes of Clofazimine Use for Rapidly Growing Mycobacterial Infections. Open Forum Infectious Diseases. 9 indexed citations
14.
Olivier, Kenneth N., David E. Griffith, Gina Eagle, et al.. (2016). Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 195(6). 814–823. 169 indexed citations
15.
Dorgan, Daniel, Gregory Tino, & Anne O’Donnell. (2015). Diagnostic approach to bronchiectasis. 4(4). 191–197. 1 indexed citations
16.
17.
Adappa, Nithin D., Alan D. Workman, Denis Hadjiliadis, et al.. (2015). T2R38 genotype is correlated with sinonasal quality of life in homozygous ΔF508 cystic fibrosis patients. International Forum of Allergy & Rhinology. 6(4). 356–361. 46 indexed citations
18.
Dorgan, Daniel & Denis Hadjiliadis. (2014). Lung transplantation in patients with cystic fibrosis: special focus to infection and comorbidities. Expert Review of Respiratory Medicine. 8(3). 315–326. 8 indexed citations
19.
Olivier, Kenneth N., Renu Gupta, Gina Eagle, et al.. (2014). Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension of Liposomal Amikacin for Inhalation (LAI) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease (NTM-LD). 3 indexed citations
20.
Calcedo, Roberto, Uta Griesenbach, Daniel Dorgan, et al.. (2013). Self-Reactive CFTR T Cells in Humans: Implications for Gene Therapy. PubMed. 24(3). 108–115. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew M. Hewitt Breakdown of academic impact, for papers by H. Blau Breakdown of academic impact, for papers by Deepti Singhal Breakdown of academic impact, for papers by Shahida Shahana Breakdown of academic impact, for papers by Hung-An Ting Breakdown of academic impact, for papers by M. Kousha Breakdown of academic impact, for papers by Katleen Martens Breakdown of academic impact, for papers by Ritu Nagpal Breakdown of academic impact, for papers by Brendan Dolan Breakdown of academic impact, for papers by Manon Ruffin
Rankless by CCL
2026